The FDA-Approved Drug Nelfinavir Inhibits Lytic Cell-Free but Not Cell-Associated Nonlytic Transmission of Human Adenovirus

• Published in: Antimicrobial agents and chemotherapy Vol. 64; no. 9
• Main Authors: Georgi, Fanny, Andriasyan, Vardan, Witte, Robert, Murer, Luca, Hemmi, Silvio, Yu, Lisa, Grove, Melanie, Meili, Nicole, Kuttler, Fabien, Yakimovich, Artur, Turcatti, Gerardo, Greber, Urs F
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 20.08.2020
• Subjects: Adenoviridae; Adenoviridae Infections; Adenovirus Infections, Human - drug therapy; Adenoviruses, Human; Antiviral Agents; Humans; Nelfinavir - pharmacology; Pharmaceutical Preparations; adenovirus death protein; drug repurposing; antiviral agents; fluorescence imaging; oncolytic virus; plaque assay; compound screening; virus transmission; membrane rupture; cell lysis

Adenoviruses (AdVs) are prevalent and give rise to chronic and recurrent disease. Human AdV (HAdV) species B and C, such as HAdV-C2, -C5, and -B14, cause respiratory disease and constitute a health threat for immunocompromised individuals. HAdV-Cs are well known for lysing cells owing to the E3 CR1-...